A filter apparatus for removing small molecule chemotherapy agents from blood is provided. The filter apparatus comprises a housing with an extraction media comprised of polymer coated carbon cores. Also provided are methods of treating a subject with cancer of an organ or region comprising administering a chemotherapeutic agent to the organ or region, collecting blood laded with chemotherapeutic agent from the isolated organ, filtering the blood laden with chemotherapeutic agent to reduce the chemotherapeutic agent in the blood and returning the blood to the subject.

A composite filter aid may include diatomaceous earth, natural glass, and a precipitated silica binder, wherein the filter aid has a permeability ranging from 3 to 20 darcys. A composite filter aid may include diatomaceous earth, perlite, and a precipitated silica binder, wherein the filter aid has an alpha density less than 15 lbs/ft.sup.3. A method for making a composite material may include blending diatomaceous earth and perlite, adding alkali silicate to the blended diatomaceous earth and perlite, and precipitating the alkali silicate as a binder to make the composite material. A method for filtering a beverage may include using a composite filter aid and/or composite material.

Organosilica materials, which are a polymer of at least one independent monomer of Formula [Z.sup.1OZ.sup.2OSiCH.sub.2].sub.3 (I), wherein each Z.sup.1 and Z.sup.2 independently represent a hydrogen atom, a C.sub.1-C.sub.4 alkyl group or a bond to a silicon atom of another monomer and at least one other trivalent metal oxide monomer are provided herein. Methods of preparing and processes of using the organosilica materials, e.g., for catalysis etc., are also provided herein.

The present invention provides porous materials for use in solid phase extractions and chromatography. In particular, the materials exhibit superior properties in the SPE analysis of biological materials. In certain aspects, the materials feature at least one hydrophobic component, at least one hydrophilic component and a average pore diameter of about 100 to about 1000 . In certain embodiments the materials also exhibit a nitrogen content from about 1% N to about 20% N. In certain embodiments, the materials feature at least one hydrophobic component, at least one hydrophilic component wherein more than 10% of the BJH surface area of the porous material is contributed by pores that have a diameter greater than or equal to 200 .

The present invention relates to calcium hydroxide particles having a total pore volume greater than 0.18 cm.sup.3/g, said total pore volume being calculated with the BJH method for a range of pores having a diameter of between 20 and 1000 , said particles being characterized in that the BJH partial pore volume for the range of pores having a diameter of between 20 and 100 corresponds to more than 20% of said BJH total pore volume.

The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.

The invention provides superficially porous metal oxide particles with precisely controlled particle density and to methods for their preparation and use, as well as to separation devices (e.g., high pressure liquid chromatography) having superficially porous particles.

Despite therapeutic advances in the field of oncology, treatment toxicity, drug resistance, and inadequate tumor site delivery restrict the benefit of cancer chemotherapy regimens. Disclosed are extracorporeal devices comprising adsorbent components that are suitable for treating a subject prior to and following administration of a dose of a chemotherapy drug, wherein the devices are configured to remove circulating factors comprising a chemotherapy drug from blood or plasma. Also disclosed herein are methods of reducing the bloodstream presence of circulating factors that mediate drug resistance, drug toxicity, and cancer metastasis, wherein circulating factors include without limitation, tumor-derived and/or chemotherapy-induced extracellular vesicles or exosomes.

The invention concerns biocompatible polymer systems comprising at least one polymer with a plurality of pores, said polymer comprising either polyol or zwitterionic groups designed to adsorb endotoxins and other inflammatory mediator molecules.

The present invention relates to a mass for trapping silicon compounds, comprising a porous alumina-based support and at least one metal chosen from the metals from groups VIB and VIIIB, and exhibiting a grain density of at least 1.20 g/ml, a specific surface of at least 300 m.sup.2/g and pores with a mean size of less than 6.5 nm, as determined by mercury porosimetry. The present invention also relates to a process for the preparation of said trapping mass and to a trapping process using said trapping mass.